EGFR and breast cancer: Formononetin derivatives exhibited potent anti-proliferative activity against triple negative breast cancer MDA-MB-231 cells and induced apoptosis by down-regulating multiple EGFR/PI3K/Akt/Bcl-2-associated death promoter (Bad), EGFR/ERK and EGFR/PI3K/Akt/β-catenin signaling pathways in breast cancer cells [149].